GlaxoSmithKline's new lung drug Anoro wins recommendation from EU regulators

GlaxoSmithKline's ($GSK) lung drug Anoro Ellipta, key to rebuilding its respiratory franchise after megablockbuster Advair meets generic competition, won recommendation from European authorities. The combination treatment for chronic obstructive pulmonary disease (COPD) is expected to hit $2 billion in sales by 2018. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.